Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Delin Zhang, Zhu Li, Tao Li, Dan Luo, Xinfu Feng, Yan Liu & Jianzhao Huang. (2018) miR-517a promotes Warburg effect in HCC by directly targeting FBP1. OncoTargets and Therapy 11, pages 8025-8032.
Read now
Read now
Articles from other publishers (12)
Amy H. Lee, Ivy L. Koh & Michelle R. Dawson. (2022) The role of exosome heterogeneity in epithelial ovarian cancer. Advances in Cancer Biology - Metastasis 4, pages 100040.
Crossref
Crossref
Mohammad Aslam Khan, Kunwar Somesh Vikramdeo, Sarabjeet Kour Sudan, Seema Singh, Annelise Wilhite, Santanu Dasgupta, Rodney Paul Rocconi & Ajay Pratap Singh. (2021) Platinum-resistant ovarian cancer: From drug resistance mechanisms to liquid biopsy-based biomarkers for disease management. Seminars in Cancer Biology 77, pages 99-109.
Crossref
Crossref
Meysam Moghbeli. (2021) MicroRNAs as the critical regulators of Cisplatin resistance in ovarian cancer cells. Journal of Ovarian Research 14:1.
Crossref
Crossref
Jia Wang, Haonan Li, Liang Wang, Jing Zhang, Man Li, Liang Qiao, Jun Zhang, Likun Liu, Cuili Zhang, Jingchun Gao & Weiling Li. (2021) Transcriptomic Analyses Reveal B-Cell Translocation Gene 2 as a Potential Therapeutic Target in Ovarian Cancer. Frontiers in Oncology 11.
Crossref
Crossref
Nalini Devarajan, Reji Manjunathan & Senthil Kumar Ganesan. (2021) Tumor hypoxia: The major culprit behind cisplatin resistance in cancer patients. Critical Reviews in Oncology/Hematology 162, pages 103327.
Crossref
Crossref
Juan Wang, Yan Li, Jin‐Hua Zhou, Fang‐Rong Shen, Xiu Shi & You‐Guo Chen. (2021) CircATRNL1 activates Smad4 signaling to inhibit angiogenesis and ovarian cancer metastasis via miR‐378. Molecular Oncology 15:4, pages 1217-1233.
Crossref
Crossref
Aleksandra Klemba, Lubomir Bodnar, Halina Was, Klaudia K. Brodaczewska, Gabriel Wcislo, Cezary A. Szczylik & Claudine Kieda. (2020) Hypoxia-Mediated Decrease of Ovarian Cancer Cells Reaction to Treatment: Significance for Chemo- and Immunotherapies. International Journal of Molecular Sciences 21:24, pages 9492.
Crossref
Crossref
Hui Hui Xie, Wen Ting Huan, Jiang Qiong Han, Wei Ru Ren & Li Hua Yang. (2019) MicroRNA-663 facilitates the growth, migration and invasion of ovarian cancer cell by inhibiting TUSC2. Biological Research 52:1.
Crossref
Crossref
Seyed Mostafa Parizadeh, Reza Jafarzadeh-Esfehani, Maryam Ghandehari, Malihe Hasanzadeh, Seyed Mohammad Reza Parizadeh, Seyed Mahdi Hassanian, Afsaneh Rezaei-Kalat, Amirsaeed Sabeti Aghabozorgi, Rana Rahimi-Kakhki, Bita Zargaran, Gordon A Ferns & Amir Avan. (2019) Circulating and Tissue microRNAs as Biomarkers for Ovarian Cancer Prognosis. Current Drug Targets 20:14, pages 1447-1460.
Crossref
Crossref
Shipeng Gong, Yongning Chen, Fanliang Meng, Yadi Zhang, Huan Wu, Chanyuan Li & Guangping Zhang. (2019) RCC2, a regulator of the RalA signaling pathway, is identified as a novel therapeutic target in cisplatin‐resistant ovarian cancer. The FASEB Journal 33:4, pages 5350-5365.
Crossref
Crossref
Gizem Ors-Kumoglu, Sultan Gulce-Iz & Cigir Biray-Avci. (2019) Therapeutic microRNAs in human cancer. Cytotechnology 71:1, pages 411-425.
Crossref
Crossref
Chuanqi Zhang, Min Wang, Cong Shi, Fanli Shi & Cheng Pei. (2018) Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin <i>via</i> the Bcl-2/Caspase-3 signaling pathway. BioScience Trends 12:3, pages 309-316.
Crossref
Crossref